Actively Recruiting
Phase II Study Evaluating Buspirone, Lofexidine, and Placebo for Opioid Withdrawal and Craving During a Residential Opioid Taper
Led by University of Maryland, Baltimore · Updated on 2026-08-24
100
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase II randomized clinical trial to study the effects of buspirone on opioid withdrawal and craving among adults with opioid use disorder OUD. This trial aims to evaluate buspirones ability to reduce withdrawal symptoms and craving, improve treatment retention, and lower relapse rates. The study compares buspirone with lofexidine and placebo during a standardized stepwise opioid taper in a residential setting. Participants will be randomly assigned to one of three groups opioid taper with buspirone, opioid taper with lofexidine, or opioid taper with placebo. Each medication starts two days before the opioid taper and continues through the taper and a post-taper observation period, lasting about 10 to 12 days. After tapering, participants may start long-term treatments like buprenorphine or extended-release naltrexone or receive referrals to other treatment programs. Throughout the study, participants complete daily questionnaires on withdrawal and craving symptoms. Craving is also measured during specific tasks in residential and outpatient phases. Safety and acceptability are monitored through adverse event reports, ECG evaluations, and participant feedback. The primary outcome is change in opioid withdrawal symptoms, with secondary outcomes including craving levels, adverse events, and medication acceptability. The total participation lasts about 10 to 12 days.
CONDITIONS
Brief Title
Evaluating Buspirone to Treat Opioid Withdrawal
Research Team
C
Cecilia Bergeria, Ph.D.
C
Caitlyn Grubb, B.S.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here